Q1 2024 Overview
- Net revenue of $1.5
billion decreased 1.7 percent year over year
- Comparable sales declined 1.2 percent year over year and
increased 4.1 percent on a two-year basis
- GAAP net loss of $46.5
million, or $(0.17) per share,
compared to GAAP net loss of $1.9
million, or $(0.01) per share
in the prior year
- Adjusted Net Income1 of $(11.8)
million, or $(0.04) per share,
compared to $14.9 million, or
$0.06 per share in the prior
year
- Adjusted EBITDA1 of $75.6
million compared to $111.0 million in the prior
year
- Operating Cash Flow of $(8.4)
million compared to $37.7
million in the prior year
- Free Cash Flow 1 of $(41.1) million compared to $(24.4) million in the prior year
SAN
DIEGO, May 22, 2024 /PRNewswire/ -- Petco Health
and Wellness Company, Inc. (Nasdaq: WOOF), a
complete partner in pet health and wellness, today
announced its first quarter 2024 financial results.
In the first quarter of 2024, Petco delivered net revenue of
$1.5 billion, down 1.7 percent versus
prior year. On an as-reported basis, the company's consumables
business was up 0.1 percent versus prior year, and services
and other business was up 4.2 percent versus prior year. Growth in
the company's consumables and services and other business was
offset by the company's supplies and companion animal business,
down 6.8 percent versus prior year. GAAP net loss in the first
quarter of 2024 was $46.5 million or
$(0.17) per share, compared to GAAP
net loss of $1.9 million or
$(0.01) per share in the prior year.
Adjusted Net Income1 was $(11.8)
million or $(0.04) per share,
compared to $14.9 million or
$0.06 per share in the prior year.
Adjusted EBITDA1 was $75.6
million compared to $111.0
million in the prior year.
"In Q1 we made meaningful progress against our strategy to
reposition the business for sustainable and profitable growth,"
said Mike Mohan, Petco's Interim
Chief Executive Officer. "The underlying value proposition of
this iconic and trusted brand remains strong, and I'm confident
that a renewed focus on retail fundamentals and effective delivery
of cost transformation will restore profitability and amplify the
competitive advantages of our differentiated approach within the
pet category."
(1)
|
Adjusted EBITDA,
Adjusted Net Income, Adjusted Earnings Per Share ("Adjusted EPS"),
and Free Cash Flow are non-GAAP financial measures. See "Non-GAAP
Financial Measures" for additional information on non-GAAP
financial measures and a reconciliation to the most comparable GAAP
measures.
|
Fiscal Q2 2024 Outlook
The company is providing Q2 guidance for revenue,
Adjusted EBITDA, and Adjusted EPS, in addition to reaffirming full
year interest, share count, and capital expenditure
expectations.
For Fiscal Q2 2024, the company expects:
Metric*
|
FQ2 2024
Guidance
|
Net Revenue
|
~ $1.525
billion
|
Adjusted EBITDA
|
~ $80
million
|
Adjusted EPS
|
~ $(0.02)
|
For Fiscal 2024 (a 52-week year), the company expects:
Metric*
|
2024
Guidance,
YoY
|
Net interest
expense
|
~$145
million
|
Capital Expenditures
|
~$140
million
|
*Assumptions in the guidance include that economic conditions,
currency rates and the tax and regulatory landscape remain
generally consistent. For fiscal 2024, our guidance anticipates a
26 percent tax rate, and 272 million weighted average diluted share
count. Adjusted EBITDA and Adjusted EPS are non-GAAP
financial measures and have not been reconciled to the most
comparable GAAP outlook because it is not possible to do so without
unreasonable efforts due to the uncertainty and potential
variability of reconciling items, which are dependent on future
events and often outside of management's control and which could be
significant. Because such items cannot be reasonably predicted with
the level of precision required, we are unable to provide outlook
for the comparable GAAP measures. Forward-looking estimates of
Adjusted EBITDA and Adjusted EPS are made in a manner consistent
with the relevant definitions and assumptions noted herein and in
our filings with the Securities and Exchange Commission.
Earnings Conference Call Webcast Information:
Management will host an earnings conference call on May 22, 2024 at 8:00 AM
Eastern Time to discuss the
company's financial results.
The conference call will be accessible through
a live webcast. Interested investors and other
individuals can access the webcast, earnings release, and earnings
presentation via the company's investor relations page at
ir.petco.com. A replay of the webcast will be archived on the
company's investor relations page through June 5, 2024 until approximately
5:00 PM Eastern Time.
About Petco, The
Health + Wellness Co.:
Founded in 1965, Petco is a category-defining health and
wellness company focused on improving the lives of pets, pet
parents and our own Petco partners. We've consistently set new
standards in pet care while delivering comprehensive pet wellness
products, services and solutions, and creating communities that
deepen the pet-pet parent bond. We operate more than 1,500 pet care
centers across the U.S., Mexico
and Puerto Rico, which offer
merchandise, companion animals, grooming, training and a growing
network of on-site veterinary hospitals and mobile veterinary
clinics. Our complete pet health and wellness ecosystem is
accessible through our pet care centers and digitally at petco.com
and on the Petco app. In tandem with Petco Love, a life-changing
organization, we work with and support thousands of local animal
welfare groups across the country and, through in-store adoption
events, we've helped find homes for nearly 7 million animals.
Forward-Looking Statements:
This earnings release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 as contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, concerning expectations, beliefs, plans, objectives,
goals, strategies, future events or performance and underlying
assumptions and other statements that are not statements of
historical fact, including, but not limited to, statements
regarding our Q2 2024 guidance, operational reset of our business,
our competitive positioning, profitability, cost action plans and
associated cost-savings. Such forward-looking statements can
generally be identified by the use of forward-looking terms such as
"believes," "expects," "may," "intends," "will," "shall," "should,"
"anticipates," "opportunity," "illustrative," or the negative
thereof or other variations thereon or comparable terminology.
Although Petco believes that the expectations and assumptions
reflected in these statements are reasonable, there can be no
assurance that these expectations will prove to be correct or that
any forward-looking results will occur or be realized. Nothing
contained in this earnings release is, or should be relied upon as,
a promise or representation or warranty as to any future matter,
including any matter in respect of the operations or business or
financial condition of Petco. All forward-looking statements are
based on current expectations and assumptions about future events
that may or may not be correct or necessarily take place and that
are by their nature subject to significant uncertainties and
contingencies, many of which are outside the control of Petco.
Forward-looking statements are subject to a number of risks,
uncertainties and other factors that could cause actual results or
events to differ materially from the potential results or events
discussed in the forward-looking statements, including, without
limitation, those identified in this earnings release as well as
the following: (i) increased competition (including from
multi-channel retailers and e-Commerce providers); (ii) reduced
consumer demand for our products and/or services; (iii) our
reliance on key vendors; (iv) our ability to attract and retain
qualified employees; (v) risks arising from statutory, regulatory
and/or legal developments; (vi) macroeconomic pressures in the
markets in which we operate, including inflation and prevailing
interest rates; (vii) failure to effectively manage our costs;
(viii) our reliance on our information technology systems; (ix) our
ability to prevent or effectively respond to a data privacy or
security breach; (x) our ability to effectively manage or integrate
strategic ventures, alliances or acquisitions and realize the
anticipated benefits of such transactions; (xi) economic or
regulatory developments that might affect our ability to provide
attractive promotional financing; (xii) business interruptions and
other supply chain issues; (xiii) catastrophic events, political
tensions, conflicts and wars (such as the ongoing conflicts in
Ukraine and the Middle East), health crises, and pandemics;
(xiv) our ability to maintain positive brand perception and
recognition; (xv) product safety and quality concerns; (xvi)
changes to labor or employment laws or regulations; (xvii) our
ability to effectively manage our real estate portfolio; (xviii)
constraints in the capital markets or our vendor credit terms;
(xix) changes in our credit ratings; (xx) impairments of the
carrying value of our goodwill and other intangible assets; (xxi)
our ability to successfully implement our operational adjustments,
achieve the expected benefits of our cost action plans and drive
improved profitability; and (xxii) the other risks, uncertainties
and other factors identified under "Risk Factors" and
elsewhere in Petco's Securities and Exchange Commission filings.
The occurrence of any such factors could significantly alter the
results set forth in these statements.
Petco cautions that the foregoing list of risks, uncertainties
and other factors is not complete, and forward-looking statements
speak only as of the date they are made. Petco undertakes no duty
to update publicly any such forward-looking statement, whether as a
result of new information, future events or otherwise, except as
may be required by applicable law, regulation or other competent
legal authority.
PETCO HEALTH AND WELLNESS COMPANY,
INC.
|
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
|
(In thousands, except
per share amounts)
|
(Unaudited and
subject to reclassification)
|
|
|
|
|
|
|
|
|
|
|
13 Weeks Ended
|
|
|
|
May 4,
2024
|
|
April 29,
2023
|
|
Percent
Change
|
|
Net sales:
|
|
|
|
|
|
|
|
Products
|
|
$ 1,279,731
|
|
$ 1,316,596
|
|
(3 %)
|
|
Services and
other
|
|
249,409
|
|
239,312
|
|
4 %
|
|
Total net sales
|
|
1,529,140
|
|
1,555,908
|
|
(2 %)
|
|
Cost of
sales:
|
|
|
|
|
|
|
|
Products
|
|
792,722
|
|
805,759
|
|
(2 %)
|
|
Services and
other
|
|
157,758
|
|
145,667
|
|
8 %
|
|
Total cost of
sales
|
|
950,480
|
|
951,426
|
|
(0 %)
|
|
Gross profit
|
|
578,660
|
|
604,482
|
|
(4 %)
|
|
Selling, general and
administrative expenses
|
|
595,442
|
|
576,865
|
|
3 %
|
|
Goodwill
impairment
|
|
—
|
|
—
|
|
N/M
|
|
Operating (loss) income
|
|
(16,782)
|
|
27,617
|
|
N/M
|
|
Interest
income
|
|
(418)
|
|
(1,177)
|
|
(64 %)
|
|
Interest
expense
|
|
36,817
|
|
37,202
|
|
(1 %)
|
|
Loss on partial
extinguishment of debt
|
|
—
|
|
441
|
|
(100 %)
|
|
Other non-operating
loss (income)
|
|
2,665
|
|
(2,819)
|
|
N/M
|
|
Loss before income taxes and income from
equity method investees
|
|
(55,846)
|
|
(6,030)
|
|
826 %
|
|
Income tax
benefit
|
|
(4,477)
|
|
(1,008)
|
|
344 %
|
|
Income from equity
method investees
|
|
(4,886)
|
|
(3,130)
|
|
56 %
|
|
Net loss attributable to Class A and B-1 common
stockholders
|
|
$
(46,483)
|
|
$
(1,892)
|
|
2,357 %
|
|
|
|
|
|
|
|
|
|
Net loss per Class A and B-1 common
share:
|
|
|
|
|
|
|
|
Basic
|
|
$
(0.17)
|
|
$
(0.01)
|
|
2,327 %
|
|
Diluted
|
|
$
(0.17)
|
|
$
(0.01)
|
|
2,327 %
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net loss
per Class A
and B-1 common share:
|
|
|
|
|
|
|
|
Basic
|
|
269,768
|
|
266,485
|
|
1 %
|
|
Diluted
|
|
269,768
|
|
266,485
|
|
1 %
|
|
PETCO HEALTH AND WELLNESS COMPANY,
INC.
|
CONSOLIDATED BALANCE SHEETS
|
(In thousands, except
per share amounts)
|
(Unaudited and
subject to reclassification)
|
|
|
|
|
|
May 4,
2024
|
|
February 3,
2024
|
ASSETS
|
|
|
|
|
Current
assets:
|
|
|
|
|
Cash and cash
equivalents
|
|
$ 89,717
|
|
$
125,428
|
Receivables, less
allowance for credit losses1
|
|
42,081
|
|
44,369
|
Merchandise
inventories, net
|
|
681,020
|
|
684,502
|
Prepaid
expenses
|
|
64,983
|
|
58,615
|
Other current
assets
|
|
26,254
|
|
38,830
|
Total current
assets
|
|
904,055
|
|
951,744
|
Fixed assets
|
|
2,177,472
|
|
2,173,015
|
Less accumulated
depreciation
|
|
(1,398,944)
|
|
(1,356,648)
|
Fixed assets,
net
|
|
778,528
|
|
816,367
|
Operating lease
right-of-use assets
|
|
1,357,576
|
|
1,384,050
|
Goodwill
|
|
980,064
|
|
980,297
|
Trade name
|
|
1,025,000
|
|
1,025,000
|
Other long-term
assets
|
|
213,819
|
|
205,694
|
Total
assets
|
|
$ 5,259,042
|
|
$
5,363,152
|
LIABILITIES AND EQUITY
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
Accounts payable and
book overdrafts
|
|
$
464,524
|
|
$
485,131
|
Accrued salaries and
employee benefits
|
|
95,027
|
|
101,265
|
Accrued expenses and
other liabilities
|
|
198,219
|
|
200,278
|
Current portion of
operating lease liabilities
|
|
307,989
|
|
310,507
|
Current portion of
long-term debt and other lease liabilities
|
|
3,680
|
|
15,962
|
Total current
liabilities
|
|
1,069,439
|
|
1,113,143
|
Senior secured credit
facilities, net, excluding current portion
|
|
1,574,486
|
|
1,576,223
|
Operating lease
liabilities, excluding current portion
|
|
1,093,136
|
|
1,116,615
|
Deferred taxes,
net
|
|
240,653
|
|
251,629
|
Other long-term
liabilities
|
|
119,019
|
|
121,113
|
Total
liabilities
|
|
4,096,733
|
|
4,178,723
|
Commitments and
contingencies
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
Class A common
stock2
|
|
233
|
|
231
|
Class B-1 common
stock3
|
|
38
|
|
38
|
Class B-2 common
stock4
|
|
—
|
|
—
|
Preferred
stock5
|
|
—
|
|
—
|
Additional
paid-in-capital
|
|
2,246,756
|
|
2,229,582
|
Accumulated
deficit
|
|
(1,093,726)
|
|
(1,047,243)
|
Accumulated other
comprehensive income
|
|
9,008
|
|
1,821
|
Total stockholders'
equity
|
|
1,162,309
|
|
1,184,429
|
Total liabilities and
stockholders' equity
|
|
$ 5,259,042
|
|
$
5,363,152
|
|
|
|
|
|
(1)
|
Allowances for credit
losses are $1,821 and $1,806, respectively
|
(2)
|
Class A common stock,
$0.001 par value: Authorized - 1.0 billion shares; Issued and
outstanding - 233.0 million and 231.2 million shares,
respectively
|
(3)
|
Class B-1 common stock,
$0.001 par value: Authorized - 75.0 million shares; Issued and
outstanding - 37.8 million shares
|
(4)
|
Class B-2 common stock,
$0.000001 par value: Authorized - 75.0 million shares; Issued and
outstanding - 37.8 million shares
|
(5)
|
Preferred stock, $0.001
par value: Authorized - 25.0 million shares; Issued and outstanding
- none
|
PETCO HEALTH AND WELLNESS COMPANY,
INC.
|
CONSOLIDATED STATEMENTS OF CASH
FLOWS
|
(In
thousands)
|
(Unaudited and
subject to reclassification)
|
|
|
|
|
|
|
|
13 Weeks Ended
|
|
|
May 4,
2024
|
|
April 29,
2023
|
Cash flows from operating
activities:
|
|
|
|
|
Net loss
|
|
$
(46,483)
|
|
$
(1,892)
|
Adjustments to
reconcile net loss to net cash (used in) provided by
operating activities:
|
|
|
|
|
Depreciation and
amortization
|
|
49,587
|
|
49,255
|
Amortization of debt
discounts and issuance costs
|
|
1,218
|
|
1,238
|
Provision for deferred
taxes
|
|
(13,365)
|
|
(5,530)
|
Equity-based
compensation
|
|
17,434
|
|
22,129
|
Impairments,
write-offs and losses on sale of fixed and other assets
|
|
3,508
|
|
4
|
Loss on partial
extinguishment of debt
|
|
—
|
|
441
|
Income from equity
method investees
|
|
(4,886)
|
|
(3,130)
|
Amounts reclassified
out of accumulated other comprehensive loss
|
|
(1,129)
|
|
575
|
Goodwill
impairment
|
|
—
|
|
—
|
Non-cash operating
lease costs
|
|
103,637
|
|
106,316
|
Other non-operating
loss (income)
|
|
2,665
|
|
(2,819)
|
Changes in assets and
liabilities:
|
|
|
|
|
Receivables
|
|
2,987
|
|
4,165
|
Merchandise
inventories
|
|
3,076
|
|
(15,508)
|
Prepaid expenses and
other assets
|
|
(4,511)
|
|
(12,115)
|
Accounts payable and
book overdrafts
|
|
(19,538)
|
|
12,582
|
Accrued salaries and
employee benefits
|
|
(5,474)
|
|
18,982
|
Accrued expenses and
other liabilities
|
|
5,902
|
|
(8,736)
|
Operating lease
liabilities
|
|
(104,181)
|
|
(130,297)
|
Other long-term
liabilities
|
|
1,139
|
|
1,991
|
Net cash (used in)
provided by operating activities
|
|
(8,414)
|
|
37,651
|
Cash flows from investing
activities:
|
|
|
|
|
Cash paid for fixed
assets
|
|
(32,641)
|
|
(62,050)
|
Cash paid for
acquisitions, net of cash acquired
|
|
(100)
|
|
(725)
|
Proceeds from
investments
|
|
998
|
|
—
|
Net cash used in
investing activities
|
|
(31,743)
|
|
(62,775)
|
Cash flows from financing
activities:
|
|
|
|
|
Borrowings under
long-term debt agreements
|
|
173,000
|
|
—
|
Repayments of
long-term debt
|
|
(173,000)
|
|
(35,000)
|
Debt refinancing
costs
|
|
(2,955)
|
|
—
|
Payments for finance
lease liabilities
|
|
(1,444)
|
|
(1,250)
|
Proceeds from employee
stock purchase plan and stock option exercises
|
|
830
|
|
1,378
|
Tax withholdings on
stock-based awards
|
|
(2,059)
|
|
(2,210)
|
Net cash used in
financing activities
|
|
(5,628)
|
|
(37,082)
|
|
|
|
|
|
Net decrease in cash,
cash equivalents and restricted cash
|
|
(45,785)
|
|
(62,206)
|
Cash, cash equivalents
and restricted cash at beginning of period
|
|
136,649
|
|
213,727
|
Cash, cash equivalents
and restricted cash at end of period
|
|
$
90,864
|
|
$ 151,521
|
NON-GAAP FINANCIAL MEASURES
The following information provides definitions and
reconciliations of the non-GAAP financial measures presented in
this earnings release to the most directly comparable financial
measures calculated and presented in accordance with generally
accepted accounting principles (GAAP). The company has provided
this non-GAAP financial information, which is not calculated or
presented in accordance with GAAP, as information supplemental and
in addition to the financial measures presented in this earnings
release that are calculated and presented in accordance with GAAP.
Such non-GAAP financial measures should not be considered superior
to, as a substitute for or alternative to, and should be considered
in conjunction with, the GAAP financial measures presented in this
earnings release. The non-GAAP financial measures in this earnings
release may differ from similarly titled measures used by other
companies.
The tables below reflect the calculation of Adjusted EBITDA,
Adjusted Net Income, and Adjusted EPS, as applicable, for the
thirteen weeks ended May 4, 2024
compared to the thirteen weeks ended April
29, 2023, respectively.
Adjusted EBITDA and Trailing Twelve Month Adjusted
EBITDA
Adjusted EBITDA, including Trailing Twelve Month Adjusted
EBITDA, is considered a non-GAAP financial measure under the
Securities and Exchange Commission's (SEC) rules because it
excludes certain amounts included in net income calculated in
accordance with GAAP. Management believes that Adjusted EBITDA is a
meaningful measure to share with investors because it facilitates
comparison of the current period performance with that of the
comparable prior period. In addition, Adjusted EBITDA affords
investors a view of what management considers to be Petco's core
operating performance as well as the ability to make a more
informed assessment of such operating performance as compared with
that of the prior period. Please see the company's Annual Report on
Form 10-K for the fiscal year ended February
3, 2024 filed with the SEC on April
3, 2024 for additional information on Adjusted EBITDA.
(dollars in thousands)
|
|
13 Weeks Ended
|
Reconciliation of Net Loss Attributable to Class A
and B-1
Common Stockholders to Adjusted
EBITDA
|
|
May 4,
2024
|
|
April 29,
2023
|
Net loss attributable to Class A and B-1 common
stockholders
|
|
$
(46,483)
|
|
$
(1,892)
|
Add
(deduct):
|
|
|
|
|
Interest expense,
net
|
|
36,399
|
|
36,025
|
Income tax
benefit
|
|
(4,477)
|
|
(1,008)
|
Depreciation and
amortization
|
|
49,587
|
|
49,255
|
Income from equity
method investees
|
|
(4,886)
|
|
(3,130)
|
Loss on partial
extinguishment of debt
|
|
—
|
|
441
|
Goodwill
impairment
|
|
—
|
|
—
|
Asset impairments and
write offs
|
|
3,508
|
|
4
|
Equity-based
compensation
|
|
17,434
|
|
22,129
|
Other non-operating
loss (income)
|
|
2,665
|
|
(2,819)
|
Mexico joint venture
EBITDA (1)
|
|
10,496
|
|
8,734
|
Acquisition and
divestiture-related costs (2)
|
|
3,719
|
|
—
|
Other costs
(3)
|
|
7,682
|
|
3,287
|
Adjusted EBITDA
|
|
$
75,644
|
|
$ 111,026
|
Net sales
|
|
$ 1,529,140
|
|
$ 1,555,908
|
Net margin
(4)
|
|
(3.0 %)
|
|
(0.1 %)
|
Adjusted EBITDA
Margin
|
|
4.9 %
|
|
7.1 %
|
(dollars in thousands)
|
|
Trailing Twelve Months
|
Reconciliation of Net (Loss) Income Attributable to
Class A and B-1
Common Stockholders to Adjusted
EBITDA
|
|
May 4,
2024
|
|
February 3,
2024
|
|
April 29,
2023
|
Net (loss) income attributable to Class A and B-1
common stockholders
|
|
$
(1,324,801)
|
|
$
(1,280,210)
|
|
$
64,216
|
Add
(deduct):
|
|
|
|
|
|
|
Interest expense,
net
|
|
147,878
|
|
147,504
|
|
117,022
|
Income tax (benefit)
expense
|
|
(31,082)
|
|
(27,613)
|
|
24,339
|
Depreciation and
amortization
|
|
201,114
|
|
200,782
|
|
196,116
|
Income from equity
method investees
|
|
(17,944)
|
|
(16,188)
|
|
(12,943)
|
Loss on partial
extinguishment of debt
|
|
479
|
|
920
|
|
441
|
Goodwill
impairment
|
|
1,222,524
|
|
1,222,524
|
|
—
|
Asset impairments and
write offs
|
|
6,337
|
|
2,833
|
|
1,834
|
Equity-based
compensation
|
|
77,164
|
|
81,859
|
|
70,691
|
Other non-operating
loss (income)
|
|
757
|
|
(4,727)
|
|
10,162
|
Mexico joint venture
EBITDA (1)
|
|
39,988
|
|
38,226
|
|
31,540
|
Acquisition and
divestiture-related costs (2)
|
|
3,719
|
|
—
|
|
13,078
|
Other costs
(3)
|
|
39,588
|
|
35,193
|
|
6,104
|
Adjusted EBITDA
|
|
$
365,721
|
|
$
401,103
|
|
$ 522,600
|
Net sales
|
|
$
6,228,516
|
|
$
6,255,284
|
|
$ 6,115,884
|
Net margin
(4)
|
|
(21.3 %)
|
|
(20.5 %)
|
|
1.0 %
|
Adjusted EBITDA
Margin
|
|
5.9 %
|
|
6.4 %
|
|
8.5 %
|
Adjusted Net Income and Adjusted EPS
Adjusted Net Income and Adjusted diluted Earnings Per Share
attributable to Petco common stockholders (Adjusted EPS) are
considered non-GAAP financial measures under the SEC's rules
because they exclude certain amounts included in the net income
attributable to Petco common stockholders and diluted earnings per
share attributable to Petco common stockholders calculated in
accordance with GAAP. Management believes that Adjusted Net Income
and Adjusted EPS are meaningful measures to share with investors
because they facilitate comparison of the current period
performance with that of the comparable prior period. In addition,
Adjusted Net Income and Adjusted EPS afford investors a view of
what management considers to be Petco's core earnings performance
as well as the ability to make a more informed assessment of such
earnings performance with that of the prior period.
(in thousands, except per share
amounts)
|
|
13 Weeks Ended
|
Reconciliation of Diluted EPS to Adjusted
EPS
|
|
May 4, 2024
|
|
April 29, 2023
|
|
|
Amount
|
|
Per share
|
|
Amount
|
|
Per share
|
Net loss attributable to common stockholders /
diluted EPS
|
|
$
(46,483)
|
|
$
(0.17)
|
|
$
(1,892)
|
|
$
(0.01)
|
Add
(deduct):
|
|
|
|
|
|
|
|
|
Income tax
benefit
|
|
(4,477)
|
|
(0.02)
|
|
(1,008)
|
|
(0.01)
|
Loss on partial
extinguishment of debt
|
|
—
|
|
—
|
|
441
|
|
0.00
|
Goodwill
impairment
|
|
—
|
|
—
|
|
—
|
|
—
|
Asset impairments and
write offs
|
|
3,508
|
|
0.01
|
|
4
|
|
0.00
|
Equity-based
compensation
|
|
17,434
|
|
0.07
|
|
22,129
|
|
0.10
|
Other non-operating
loss (income)
|
|
2,665
|
|
0.01
|
|
(2,819)
|
|
(0.01)
|
Acquisition and
divestiture-related costs (2)
|
|
3,719
|
|
0.01
|
|
—
|
|
—
|
Other costs
(3)
|
|
7,682
|
|
0.03
|
|
3,287
|
|
0.01
|
Adjusted pre-tax (loss)
income / diluted (loss) earnings per share
|
|
$ (15,952)
|
|
$ (0.06)
|
|
$ 20,142
|
|
$ 0.08
|
Income tax (benefit)
expense at 26% normalized tax rate
|
|
(4,148)
|
|
(0.02)
|
|
5,237
|
|
0.02
|
Adjusted Net (Loss) Income / Adjusted
EPS
|
|
$
(11,804)
|
|
$
(0.04)
|
|
$
14,905
|
|
$
0.06
|
Free Cash Flow
Free Cash Flow is a non-GAAP financial measure that is
calculated as net cash provided by operating activities less cash
paid for fixed assets. Management believes that Free Cash Flow,
which measures the ability to generate additional cash from
business operations, is an important financial measure for use in
evaluating the company's financial performance.
The table below reflects the calculation of Free Cash Flow for
the thirteen weeks ended May 4, 2024
compared to the thirteen weeks ended April
29, 2023, respectively.
(in thousands)
|
|
13 Weeks Ended
|
|
|
May 4,
2024
|
|
April 29,
2023
|
Net cash (used in)
provided by operating activities
|
|
$
(8,414)
|
|
$
37,651
|
Cash paid for fixed
assets
|
|
(32,641)
|
|
(62,050)
|
Free Cash Flow
|
|
$
(41,055)
|
|
$
(24,399)
|
Non-GAAP Financial Measures Footnotes
(1)
|
Mexico Joint Venture
EBITDA represents 50 percent of the entity's operating results for
all periods, as adjusted to reflect the results on a basis
comparable to Adjusted EBITDA. In the financial statements, this
joint venture is accounted for as an equity method investment and
reported net of depreciation and income taxes because such a
presentation would not reflect the adjustments made in the
calculation of Adjusted EBITDA, we include the 50 percent interest
in the company's Mexico joint venture on an Adjusted EBITDA basis
to ensure consistency. The table below presents a reconciliation of
Mexico joint venture net income to Mexico joint venture
EBITDA.
|
|
|
|
|
13 Weeks Ended
|
(in thousands)
|
|
May 4,
2024
|
|
April 29,
2023
|
Net income
|
|
$
9,555
|
|
$
6,259
|
Depreciation
|
|
6,948
|
|
5,708
|
Income tax
expense
|
|
3,456
|
|
4,074
|
Foreign currency
loss
|
|
479
|
|
127
|
Interest expense,
net
|
|
553
|
|
1,300
|
EBITDA
|
|
$ 20,991
|
|
$ 17,468
|
50% of EBITDA
|
|
$
10,496
|
|
$
8,734
|
|
|
(2)
|
Acquisition and
divestiture-related costs include direct costs resulting from
acquiring, integrating, or divesting businesses. These include
third-party professional and legal fees, losses on sales of
divestitures, and other integration-related costs that would not
have otherwise been incurred as part of the company's
operations.
|
(3)
|
Other costs include, as
incurred: restructuring costs and restructuring-related severance
costs; legal reserves associated with significant, non-ordinary
course legal or regulatory matters; and costs related to certain
significant strategic transactions.
|
(4)
|
We define net margin as
net income attributable to Class A and B-1 common stockholders
divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA
divided by net sales.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/petco-health--wellness-company-inc-reports-first-quarter-2024-earnings-results-302152087.html
SOURCE Petco - Investor Relations